These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 27839)

  • 21. Serum concentrations and clinical effects of risperidone in schizophrenic patients in Singapore--a preliminary report.
    Lee HS; Tan CH; Khoo YM; Chee KT; Wong KE; Chong SA; Mahendran R; Yap JL; Low BL; Choo CH; Chan A
    Br J Clin Pharmacol; 1999 Apr; 47(4):460-1. PubMed ID: 10366241
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical effectiveness of piperacetazine injection in schizophrenic patients: a controlled study.
    Kulkarni AS
    Adv Biochem Psychopharmacol; 1974; 9(0):691-9. PubMed ID: 4151770
    [No Abstract]   [Full Text] [Related]  

  • 23. [Parenteral form of pipothiazine in the treatment of endogenous psychoses].
    Matkowski K; Martenka E; Nobis T
    Psychiatr Pol; 1984; 18(6):567-70. PubMed ID: 6152666
    [No Abstract]   [Full Text] [Related]  

  • 24. Pipotiazine palmitate: an evaluation of a new long acting intramuscular antipsychotic agent in severely ill schizophrenic patients.
    Gallant DM; Mielke D; Bishop G; Oelsner T; Guerrero-Figueroa R
    Dis Nerv Syst; 1975 Apr; 36(4):193-6. PubMed ID: 1090427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Anesthetic experience with 62 schizophrenic patients on chronic antipsychotic drugs].
    Matsuki A; Kimura K; Maeda A; Kami T; Wakayama S
    Masui; 1987 Nov; 36(11):1808-12. PubMed ID: 2895818
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of phenothiazines on anxiety and cognition in schizophrenia.
    Meadow A; Donlon PT; Blacker KH
    Dis Nerv Syst; 1975 Apr; 36(4):203-8. PubMed ID: 234827
    [No Abstract]   [Full Text] [Related]  

  • 27. Central atropine-like toxicity in combined psychotropic drug administration.
    el-Yousef MK; Davis JM; Janowsky DS; Fann WE
    J Tenn Med Assoc; 1972 Aug; 65(8):719. PubMed ID: 4152620
    [No Abstract]   [Full Text] [Related]  

  • 28. Results of a multicenter AMDP study with fluperlapine in schizophrenic patients.
    Woggon B; Heinrich K; Küfferle B; Müller-Oerlinghausen B; Pöldinger W; Rüther E; Schied HW
    Arzneimittelforschung; 1984; 34(1A):122-4. PubMed ID: 6145427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Partial response to antipsychotic treatment: the patient with enduring symptoms.
    Emsley RA
    J Clin Psychiatry; 1999; 60 Suppl 23():10-3. PubMed ID: 10625194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparative study with pipothiazine palmitate and fluphenazine enanthate in the treatment of schizophrenic patients.
    Jain RC; Ananth JV; Lehmann HE; Ban TA
    Curr Ther Res Clin Exp; 1975 Oct; 18(4):585-9. PubMed ID: 241609
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical differences among phenothiazines in schizophrenics. Introduction: specific indications for antipsychotics: elusive end of the rainbow.
    Hollister LE
    Adv Biochem Psychopharmacol; 1974; 9(0):667-73. PubMed ID: 4151921
    [No Abstract]   [Full Text] [Related]  

  • 32. A random-effects mixture model for classifying treatment response in longitudinal clinical trials.
    Xu W; Hedeker D
    J Biopharm Stat; 2001 Nov; 11(4):253-73. PubMed ID: 12018779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of phenothiazines in managing aggressive episodes in schizophrenic patients.
    Simeon J; Wadud A; Itil T
    Hosp Community Psychiatry; 1975 Sep; 26(9):574. PubMed ID: 238907
    [No Abstract]   [Full Text] [Related]  

  • 34. Spectrum analysis of the EEG in schizophrenic patients.
    Vanderheeren F; Van Rompu E; Jannes C; Delaunois AL
    Arzneimittelforschung; 1979; 29(9):1437-9. PubMed ID: 42419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pigmented hyperkeratosis among schizophrenic patients treated with nicotinic acid.
    Wittenborn JR; Nenno R; Rothberg H; Shelley WB
    Adv Biochem Psychopharmacol; 1974; 9(0):295-300. PubMed ID: 4151765
    [No Abstract]   [Full Text] [Related]  

  • 36. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum neuroleptic levels in the maintenance treatment of schizophrenia.
    Brown WA; Laughren T
    Psychopharmacol Bull; 1983; 19(1):76-8. PubMed ID: 6131471
    [No Abstract]   [Full Text] [Related]  

  • 38. Short-term double-blind trial of pipothiazine palmitate and haloperidol in the acute phase of schizophrenia.
    Bechelli LP; Navas-Filho F
    Encephale; 1986; 12(3):121-5. PubMed ID: 2876879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proceedings: Drugs, neurotransmitters, and psychosis.
    Snyder SH
    Psychopharmacol Bull; 1974 Oct; 10(4):4-5. PubMed ID: 4154472
    [No Abstract]   [Full Text] [Related]  

  • 40. The treatment of lobotomized schizophrenic patients with butaperazine.
    Holden JM; Itil TM; Keskiner A
    Curr Ther Res Clin Exp; 1969 Jul; 11(7):418-28. PubMed ID: 4390417
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.